* 中国生物科技公司--和铂医药2142.HK周一早盘高开4.2%，随后涨幅扩大至8.7%。
* 该公司此前公告称，向日本制药公司大冢制药授予在全球范围内（不包括大中华区，即中国大陆、香港、台湾及澳门）开发、制造及商业化HBM7020的独家授权。HBM7020具有可广泛应用于免疫性与肿瘤疾病的强效细胞活性。
和铂医药有权获得总计4,700万美元的首期及近期付款，并在实现特定开发及商业化里程碑时，有权获得高达623百万美元的潜在里程碑付款，以及未来净销售额的分层特许权使用费。
* 和铂医药今年迄今暴涨341.4%，同期恒生指数.HSI大幅上扬16.7%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌1.8%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 吴云凌)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.